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Abstract A previously developed poly-L-lactide scaffold re-
leasing granulocyte colony-stimulating factor (PLLA/GCSF)
was tested in a rabbit chronic model of myocardial infarction
(MI) as a ventricular patch. Control groups were constituted by
healthy, chronic MI and nonfunctionalized PLLA scaffold.
PLLA-based electrospun scaffold efficiently integrated into a
chronic infarcted myocardium. Functionalization of the bio-
polymer with GCSF led to increased fibroblast-like vimentin-
positive cellular colonization and reduced inflammatory cell
infiltration within the micrometric fiber mesh in comparison to
nonfunctionalized scaffold; PLLA/GCSF polymer induced an
angiogenetic process with a statistically significant increase in
the number of neovessels compared to the nonfunctionalized
scaffold; PLLA/GCSF implanted at the infarcted zone induced
a reorganization of the ECM architecture leading to connective
tissue deposition and scar remodeling. These findings were
coupled with a reduction in end-systolic and end-diastolic vol-
umes, indicating a preventive effect of the scaffold on ventricu-
lar dilation, and an improvement in cardiac performance.
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Introduction
Cardiac tissue damage associated to a myocardial infarction
(MI) origins a biological cascade leading to substitution of
cardiac muscle with scar formation [1, 2]. In the initial stages
characterized by a general inflammatory activation, cardiac
cells and stem cells recruited from bone marrow show high
proliferation and regenerative potential. However, these com-
pensatory mechanisms lead at the same time to the activation
of resident fibroblast resulting in extracellular matrix (ECM)
deposition to replace tissue loss and avoid ventricular dilation.
Progressive myocardial degeneration with formation of a non-
functional scar follows, with alteration of the elastic and me-
chanical properties of the ventricle until pump failure and
dysfunction of the conduction system, leading to potential
re-entrant circuits and increasing the risk of ventricular tachy-
arrhythmias, which represent the major cause for death in
heart failure patients [2–4]. Recently, granulocyte colony-
stimulating factor (GCSF), a growth factor routinely used in
clinical hematology and known to mobilize endogenous bone
marrow (BM)-derived cells, fueled the interest of scientists
because of some direct actions on cardiac cells [5–9].
In the field of TE, the idea of a biomimetic approach based
on the simulation of the ECM along with the guidance of
resident and stem cell differentiation aided by a growth factor
is emerging as a new perspective [10, 11]. The rationale un-
derlying this approach concerned the possibility to exploit the
endogenous reparative capabilities of the body and to guide
these regenerative resources toward tissue restoration by
means of a tailored absorbable material [11, 12]. The impor-
tance to concentrate and spatially organize a biological medi-
ator within a 3D ambient, which resembles the native tissue
histoarchitecture, has been recently pointed out [10, 13, 14].
Functionalization of the scaffold with growth factors and other
biological signals could permit to produce a drug-delivering
device providing a structured support to guide cell differenti-
ation and orient tissue regeneration. This idea acquires partic-
ular significance in cardiac tissue engineering, in which artifi-
cial myocardial patches might be used to prevent geometrical
remodeling of the infarcted myocardium and to promote myo-
cardial restoration. In this context, an engineered functional-
ized myocardium could provide a mechanical mean for ven-
tricular restraint avoiding its dilation. At the same time, it
could create a biological ambient suitable to sustain the pro-
liferative capacity of the cells surrounding the infarcted area
and a molecular pathway to stimulate cell differentiation [15].
Considering the reported effects of a GCSF cardiac cell
proliferation and its beneficial action of the prevention of con-
ductance aberration after MI, we realized a GCSF-releasing
polymeric scaffold in poly-L-lactide (PLLA) electrospun fi-
bers and skeletal myoblasts have been cultured in it to obtain
a tissue-engineered cardiac graft (TECG) [16]. The
electrospinning technique used to manufacture the scaffold
allowed for the creation of fibrillary matrix with ultrastructural
properties featuring in micrometric scale and thus closely sim-
ulating the native ECM histoarchitecture [17]. Skeletal myo-
blasts seeded in the scaffold acquired morphological charac-
teristics of cardiomyocytes. Cells appeared elongated, and
presence of Cx43-positive cellular junctions resembling the
gap junctions normally encountered in the myocardium could
be observed. These findings, coupled with the expression of
cardiac specific isoform of troponin-I, reliably indicate the
in vitro promotion of a cardiomyocyte-like profile in this
GCSF-functionalized scaffold [16].
Considering the demonstration of the in vitro effectiveness
of the functionalized biopolymer previously developed, in the
present study, we sought to evaluate the effect of the implan-
tation of a GCSF-releasing microstructured biomaterial, pre-
pared as a ventricular patch, in an animal model of chronic
myocardial infarction.
Materials and Methods
Scaffold Preparation and Characterization
GCSF-releasing PLLA scaffolds (PLLA/GCSF sample) were
prepared by electrospinning as previously described [18].
Briefly, GCSF (Filgrastim, 30 MUI/mL, sodium salt,
Amgen, Thousand Oaks, CA) was combined to a 13% w/w
PLLA (Sigma-Aldrich, St. Louis, MO) polymer solution at a
concentration of 250 UI/g, corresponding to the dosage rou-
tinely used in literature and in clinical settings [19]. Procedural
parameters [16] and sterilization techniques [20] are described
elsewhere.
Pristine PLLA scaffolds (PLLA/CTRL sample) were
manufactured using the same experimental conditions to ob-
tain a control for biological experiments.
Mechanical and microstructural characterization of the ma-
terials, as well as determination of the drug release profile,
have been reported elsewhere [18] and performed by means
of field emission scanning electron microscopy (FE-SEM),
longitudinal uniaxial testing according to Sell et al. with peak
stress (PS) and strain at failure (SF) evaluation [21], and spe-
cific ELISA assay for GCSF quantitation.
Experimental Protocol
1. General Overview
Estimation of the total number of rabbits (replicates per
group) was performed via an inverse power analysis by cal-
culating the number required to detect a significant difference
in biological endpoints between the control and the experi-
mental groups. For this project, data generated by Tan et al.
evaluating the effectiveness of a MSC-seeded intestinal
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submucosa in a model of rabbit myocardial infarction in terms
of left ventricular function and tissutal capillary density in
comparison to control were used [22]. This calculation gave
a sample size of four animal surgeries per condition tested.
Considering 30% mortality and four experimental groups, a
total of 24 adult male New Zealand white rabbits weighting
1.8–2.1 kg were purchased (Charles River Laboratory) and
housed under controlled conditions and normal diet for
3 weeks before experimentation.
Therefore, total animals were randomly assigned to four
groups. Group 1 was made of four healthy control
(HEALTHY); group 2 consisted of six animals to be used as
a chronic MI control group (MI/CTRL); group 3 was made of
seven animals that would receive a pristine PLLA
(PLLA/CTRL) patch; and group 4 was made of seven animals
that would undergo PLLA-GCSF-functionalized patch
(PLLA/GCSF) implantation. As discussed above, patches
were planned to be implanted 4 weeks after MI induction.
Numerosity of each group was defined at the beginning of
the study protocol to ensure that, even in case of adverse
events, an adequate number of subjects completed the proto-
col in each group.
Study design consisted in a first phase of creation of a
chronicized localizedMI through coronary permanent ligation
via left thoracotomy followed by a second phase, 4 weeks
after MI, of implantation of a GCSF-releasing poly-L-lactic
acid microstructured patch through median sternotomy. Only
animals developing a left ventricular dysfunction with ejection
fraction inferior to 35% gained access to the second phase.
Timing for second surgery was defined according to the re-
ported findings of stabilization of cardiac remodeling process
[23] and achievement of a histological plateau in the infarcted
myocardium 4 weeks after MI induction [24]. To control for
potential biases arising from the use of the biomaterial, results
were compared also to a nonfunctionalized, pristine PLLA
patch.
Blood test and imaging and functional assessment through
echocardiography and CT scans were performed at baseline,
4 weeks after MI induction and 2 weeks following patch im-
plantation before study termination. All procedures, care, and
handling of the animals were reviewed and approved by the
Institutional Animal Care and Use Committee of the Regina
Elena Institute.
Operative Procedures
1. Anesthesia
An optimized anesthesia protocol was selected in order to
guarantee stabilization of cardiovascular function during the
open chest procedure [25]. Anesthesia was inducted by intra-
muscular (i.m.) administration of ketamine hydrochloride
(25 mg/kg of body weight) and xylazine hydrochloride
(15 mg/kg). After disappearance of the pedal reflex in the
hindlimbs, rabbits were placed on a warming operative plat-
form (37 °C) in the supine position. A 23-gauge vascular
access was obtained through the marginal vein of the ear.
The hair on the anterior and lateral chest wall and on the
anterior cervical region was trimmed with an electric clipper.
The skin leads of a custom-built electrocardiographic appara-
tus were attached on both fore limbs and on the left hind limb,
and the electrocardiogram was monitored. Before skin inci-
sion, one dose of enorfloxacin (100 mg/kg) was administered
intramuscularly for prophylaxis against surgical infection.
Intravenous anesthesia with propofol (0.6 mg kg−1 min−1)
and fentanyl (0.48 μg kg−1 min−1) was given and used as
maintenance. The trachea was cannulated for artificial respi-
ration. Positive pressure artificial respiration was started im-
mediately with room air with the use of a stroke volume of
20 mL/kg and at a rate of 55 strokes/min as previously de-
scribed [26] (Harvard Apparatus, Holliston, MA).
2. Myocardial Infarction Protocol
Surgery was performed using aseptic techniques with ster-
ile instruments. The skin of the anterior and lateral chest wall
was aseptically prepped with a povidone-iodine solution. To
induce reliable MI, studies of Podesser et al. demonstrating
the interindividual variability of rabbit coronary anatomy and
the differences in regional myocardial perfusion distribution
[27] together with protocols developed by Lee et al. to obtain a
reproducible myocardial damage according to the ramification
pattern of the coronary arteries [28] were used. Briefly, a left
thoracotomy at the fourth intercostal space was performed. An
incision was made at the cardiac sac to expose the myocardial
ventricular wall, and the heart was gently exteriorized by peri-
cardial suspension 2-0 silk sutures; the left coronary artery
was then identified by lifting the ventricular wall upward
and the coronary ramification pattern evaluated. According
to the bifurcation or trifurcation asset found, the major branch
supplying blood to the left ventricle and cardiac apex was then
ligated at a defined site between the starting point of the major
branch and the cardiac apex using a 6-0 monofilament poly-
propylene suture (Prolene™, Ethicon, Johnson & Johnson,
Somerville, NJ, USA) as described by Lee et al. [28] The
ligated artery should have corresponded to the posterolateral
or lateral branch of the left coronary artery. Myocardial ische-
mia was confirmed by ST-segment elevation on the ECG and
regional cyanosis and/or bulging of the myocardial surface.
Lidocaine 1 mg/kg was given intravenously 2 min before and
immediately after ligation to prevent ventricular arrhythmias.
Left pleural drainage was posed in place applying negative
pressure. Interrupted 2-0 resorbable suture was used to ap-
proximate the ribs. The muscle layer was reformed using
semi-interrupted 3-0 sutures to form a complete seal. The skin
was closed with semi-interrupted 4-0 Nylon sutures. A dab of
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povidone-iodine solution was placed on the suture line. After
closure of the chest, the animals were allowed to recover for
30 min on a warming pad and were weaned from artificial
ventilation. The surgical procedure was completed within
30 min after the initiation of anesthesia. When responsive to
stimuli and able to maintain an upright posture, rabbits were
returned to the home cage and analgesia initiated with
buprenorphine (0.5 mg/kg) and paracetamol (1 mg/kg).
3. Patch Implantation
Four weeks after MI induction, rabbits underwent similar
anesthetic protocol and were placed in supine position and the
chest aseptically prepped with a povidone-iodine solution.
One percent lidocaine was injected into the subcutaneous area
overlying the sternum to enhance analgesia and to prevent the
occurrence of myocardial arrhythmia. After a midline muscle
and skin incision was made over the sternum, the xiphoid
process was carefully detached from the sternal part of the
diaphragm. A median sternotomy was then performed; the
median incision went straight down the xiphoid process to-
ward the jugular notch of the sternum exactly along the mid-
line of the sternum so that injury to the parietal pleura was
avoided. Sternal retractors were then used to spread the sternal
edges and maintain surgical exposure. Adhering tissue around
the myocardium was carefully removed, and the infarcted re-
gion was identified at the level of previous Prolene suture.
Infarcted zone was scarified, and PLLA or PLLA/GCSF patch
was sutured within the injured myocardium with 7-0 Prolene
suture. Group MI/CTRL underwent median sternotomy and
all the procedures without patch implantation. One percent
lidocaine was given intravenously before and after patch im-
plantation. Chest drainages were placed if necessary, and ster-
num was closed with four interrupted sutures using 1-0 Vicryl
(Ethicon) suture with a taper point needle in order not to dam-
age to the internal thoracic arteries and veins. Muscle layers
and skin were then closed with continuous suture using 4-0
nylon with a cutting needle. The rabbits were allowed to re-
cover and were weaned from artificial ventilation. After com-
plete recovery from anesthesia, analgesia protocol with
buprenorphine(0.5 mg/kg) and paracetamol (1 mg/kg) was
initiated.
Functional Assessment
1. Echocardiography
Echocardiographic evaluation was performed at baseline,
4 weeks after the induction of MI, and at the end of the study
protocol in each subject. Functional assessment was achieved
by echocardiography, performed by a blinded investigator on
control and treatment groups using a Sequoia C256 system
(Acuson, Mountain View, CA, USA) equipped with a 6-MHz
linear-array transducer (15L8). Standard 2D and M-mode
transthoracic images were recorded at the level of the papillary
muscles. All measurements were performed according to the
American Society for Echocardiology leading-edge technique
and averaged on three consecutive cardiac cycles. Regional
wall motion, post-ischemic papillary muscle dysfunction with
mitral valve insufficiency, and ventricular diameters and vol-
umes were determined. End-diastolic diameter (EDD) and
end-systolic diameter (ESD) and associated volumes were
measured; fraction of shortening (FS) and ejection fraction
(EF) was calculated by ad hoc software (Acuson, Sequoia,
Mountain View, CA, USA).
2. Computerized Tomographic Angiography
Computerized tomographic angiography (CTA, Siemens
AG, Erlangen, Germany) was performed on all groups at
baseline and in all eligible subjects 4 weeks after MI induction
and 2 weeks following patch implantation or control proce-
dure. Rabbits were anesthetized with midazolam at a dose of
2 mg/kg intramuscular. ECG gating was achieved, iodinated
contrast medium was injected in the marginal ear vein, and
cardiac CT scans were obtained and reformatted in 3D using
maximum intensity projection (MIP) and volume rendering
algorithms. Ventricular volumes have been calculated by
means of Circulation Leonardo software (Siemens) according
to perpendicular axes of reconstruction. Left ventricular end-
diastolic volume (EDV), left ventricular end-systolic volume
(ESV), EF, cardiac output (CO), stroke volume (SV), and left
ventricle mass (LVM) were measured by two independent
blinded observers, and the mean for each pair of observations
was recorded. Healthy subjects were used as controls for
pairwise comparisons.
3. Histopathological Examination
Twoweeks following patch implantation (for PLLA/CTRL
and PLLA/GCSF groups) or control surgical procedure (for
MI/CTRL group), rabbits were humanely sacrificed and the
heart was exposed by median sternotomy. Heparin (2000 IU)
was administered intravenously, and the hearts were quickly
excised with the aortic root and retrogradely perfused with
heparinized saline. The hearts were cut into equal transverse
blocks from apex to base. Samples obtained were fixed in 4%
paraformaldehyde and embedded in paraffin. Progressive se-
rial sections (6 μm thick) were cut from paraffin-embedded
blocks and used for hematoxylin/eosin (H/E) staining,
Masson’s trichrome staining, silver staining (Bio-Optica,
Milan), and immunohistochemistry for vimentin, CD68, and
CD31. The number of microvessels (diameter < 20 μm) in the
infarcted area were counted in paraffin-embedded sections
with CD31 staining under light microscopy (magnification
×400). Five high-power fields in the infarcted area were
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randomly chosen, and microvessels were counted in each
field. Vascular density was expressed as the average number
of microvessels per unit area (0.2 mm2) [29]. Similarly, differ-
ential cell count for inflammatory (CD68+) cells and nonin-
flammatory fibroblast-like vimentin-positive cells have been
performed according to Peng et al. [30] and Odorfer et al. [31].
Myocardial infarction size was performed 4 weeks after MI
induction and at the end of the study as previously described
[32, 33].
Statistical Analysis
Data were processed using SPSS release 20.0 for Windows
(SPSS, Chicago, IL). Data are reported as means ± standard
deviation (SD). One-way ANOVA was used to compare
groups with different treatments, followed by multiple
pairwise comparison procedure (Tukey test) with P values
less than 0.01 considered as significance threshold.
Repeated measures ANOVA and two-way ANOVA were
performed to compare between the 4- and 6-week results
between groups. P values less than 0.05 were considered
significant.
Results
Scaffold Characterization
GCSF-releasing PLLA patch have been fully character-
ized as for their chemical, biological, and mechanical
properties in our previous work. Briefly, FE-SEM char-
acterization of the electrospun materials revealed a ho-
mogeneous distribution of porous fibers with an average
diameter of 1.30 ± 0.40 μm for PLLA/CTRL and PLLA/
GCSF samples. This fiber morphology could represent a
suitable environment for cell culturing, as simulating the
structure of native extracellular matrix, and potentially
provide similar support to cell growth and differentiation.
The stress-strain profile showed a bell-shaped curve with
a peak stress quantified at 0.188 ± 0.011 MPa and a
strain at failure of 0.319 ± 0.016. GCSF release curve
showed an initial burst, followed by a sustained release
at a much slower rate. Up to 35% of the loaded GCSF
was released at 1 week. Nontoxicity of the scaffold was
confirmed by preserved cell viability with an increase in
cell proliferation rate in a colony of C2C12 myoblasts
seeded into a GCSF-releasing patch. Efficiency was tes-
tified by the induction of significant cell changes in mor-
phology, biological phenotype, and expected expression
of cell markers (CX43) within the GCSF-releasing patch
in the experiments previously cited [16].
Mortalities
Six of the 24 rabbits died within 4 weeks after left anterior
descending artery ligation andMI induction (1 in group 2, 2 in
group 3, and 3 in group 4), and 2 rabbits were excluded after
the first echocardiography examination because their EF was
above 35% (1 in group 2 and 1 in group 3). The remaining
animals of groups 3 and 4 underwent patch implantation ac-
cording to study protocol. Therefore, each experimental group
was made up of four animals.
Echocardiography
After MI induction, all the subjects developed mitral insuffi-
ciency due to posterior-lateral papillary muscle dysfunction
consequent to MI. Additionally, general LV hypokinesia was
noted along with left atrial enlargement. Hypokinesia of the
superior portion of the interventricular septum was noted, and
signs of right ventricular overload were detected in some an-
imals, but no evidence of significant tricuspid regurgitation
was demonstrated. Apart from two subjects with EF above
35%, which were subsequently excluded from the analysis,
EF in the other subjects was below 35% (mean 30 ± 3%).
Table 1 and Fig. 1 show echocardiographic findings 4 and
6 weeks post-MI, the latter corresponds to 2 weeks after patch
implantation; both EDD and ESD significantly improved in
the PLLA/GCSF group compared to MI/CTRL and PLLA/
CTRL groups. ESD increased over time in the control and
PLLA group indicating an underlying process of LV dilation
and post-MI remodeling. In the PLLA/GCSF group, a signif-
icant decrease in the ESD was noted 2 weeks after implanta-
tion. These data were coupled with a statistically significant
improvement at 6 weeks’ control of both FS and EF in the
PLLA/GCSF group compared to both MI/CTRL and PLLA/
CTRL group.
Computerized Tomographic Angiography
A reduction in myocardial wall thickness could be observed
according to the localization of the induced MI (Fig. 2).
In the groups implanted with PLLA or PLLA/GCSF
patches , the biomater ia l could be detected as a
radiotransparent region lying over the area of wall thinning
(Figs. 3 and 4).
Measurement of EDD and ESD confirmed the findings
obtained at echocardiography with a significant reduction in
both the diameters 6 weeks after PLLA/GCSF patch implan-
tation. By synchronization with cardiac cycle, ECG-gated im-
ages were obtained showing a topographical map of myocar-
dial wall thickening and regional kinesis (Fig. 5).
EDV, ESV, EF, CO, SV, and LVM could be calculated and
are shown in Table 2. PLLA/GCSF group showed a signifi-
cant improvement of EDV with an EF of 43 ± 0.1%, and the
J. of Cardiovasc. Trans. Res. (2017) 10:47–65 51
Fig. 1 Echocardiographic evaluation of LVEDD (a), LVESD (b), FS (c), and EF (d) after 4 weeks (light gray) and 6 weeks (dark gray) after induced
myocardial infarction; the latter corresponds to 2 weeks after patch implantation. P values are shown in Table 1
Table 1 Echocardiographic
findings 4 and 6 weeks post-
myocardial infarction
(corresponds to 2 weeks after
patch implantation), withP values
referring to the difference with
PLLA/GCSF group
Parameter Group 4 weeks 6 weeks P (within group)
LVEDD (mm) MI/CTRL 18 ± 6, P = 0.599 19 ± 2, P = 0.011 0.762
PLLA/CTRL 17 ± 2, P = 0.670 16 ± 3, P = 0.550 0.599
PLLA/GCSF 16 ± 4 15 ± 1 0.645
LVESD (mm) MI/CTRL 11 ± 4, P = 0.703 12 ± 1, P = 0.005 0.645
PLLA/CTRL 11 ± 1, P = 0.550 10 ± 5, P = 0.708 0.708
PLLA/GCSF 10 ± 3 9 ± 1 0.550
LVEDV (mL) MI/CTRL 10.9 ± 1.2, P = 0.975 11.4 ± 1.3, P = 0.070 0.592
PLLA/CTRL 10.8 ± 1.3, P = 0.914 11.5 ± 1.6, P = 0.090 0.522
PLLA/GCSF 10.9 ± 1.2 9.6 ± 1.0 0.147
LVESV (mL) MI/CTRL 7.5 ± 1.3, P = 0.755 8.5 ± 1.2, P = 0.005 0.301
PLLA/CTRL 7.2 ± 1.2, P = 0.958 8.4 ± 1.3, P = 0.007 0.223
PLLA/GCSF 7.2 ± 1.3 5.0 ± 1.1 0.042
FS (%) MI/CTRL 37 ± 6, P = 0.405 30 ± 3, P < 0.001 0.082
PLLA/CTRL 42 ± 6, P = 0.573 35 ± 1, P < 0.001 0.061
PLLA/GCSF 40 ± 3 53 ± 1 <0.001
EF(%) MI/CTRL 31 ± 2, P = 0.078 25 ± 2, P < 0.001 0.005
PLLA/CTRL 33 ± 2, P = 0.506 27 ± 1, P < 0.001 0.001
PLLA/GCSF 34 ± 2 48 ± 1 <0.001
P values in the separate column represents the statistical significance of the within group difference
LVEDD left ventricle end diastolic diameter, LVESD left ventricle end systolic diameter, FS fraction of shortening,
EF ejection fraction
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calculated CO improved to 0.51 ± 0.5 L/min. LVM was sig-
nificantly improved in the PLLA/GCSF group compared to
MI/CTRL group and PLLA/CTRL group.
Histology
Intraoperative findings and macroscopic evaluation are shown
in Fig. 6. Infarcted area is clearly visible, and patch appears to
be juxtaposed to the myocardium. Myocardial infarction size
measurement 4 weeks after MI induction and at the end of the
study are reported in Fig. 7. No statitistically significant dif-
ference among groups could be observed soon after MI induc-
tion (at 4 months) indicating the achievement of a similar
baseline extension of the infaction across the groups in terms
of infarction size and transmurality. However, at the end of the
study, the physiological process of myocardial expansion oc-
curring in the MI/CTRL group seemed to have been attenuatd
or counteracted in both the groups treated with patch implan-
tation, although the PLLA/GCSF group showed the most sig-
nificant reduction in MI scar sized. This finding was coupled
with the previosly mentioned improvement in EDV and
LVEED indicating a lesser extent of post-MI ventricular
dilation.
Hematoxylin-eosin staining in control chronic MI showed
a cicatricial region characterized by cellular disarray and
caotic deposition of extracellular matrix. Myocardial tissue
showed typical features of chronic infarction with nuclear
pyknosis, lipofuscin deposition, and intercellular calcifica-
tions. In the PLLA/GCSF group, the reduction of scar tissue
is accompanied by an increase in cellularity and by a more
organized fiber deposition, resulting in more loose collagen
with fewer calcifications and increased angiogenesis (Figs. 8
and 9). Qualitative assessment of ECM with Masson’s and
Silver staining showed denser, thicker, and scarcely organized
collagen bundles in the MI/CTRL and PLLA/CTRL group at
the level of the scar, while the PLLA/GCSF was characterized
by a looser reticular organization of the collagen which ap-
peared interspread among several neovessels (Fig. 9). With
the aid of a light polarizator and in virtue of polymer
refrangency, it was possible to study the cellular polymeric
fiber relation within the patch (Fig. 10). Also, the PLLA/
GCSF patch appeared cellularized with elements of different
morphology and derivation. On the other hand, in the PLLA/
Fig. 2 Volume-rendering CT
reconstructions. Positioning of the
subject (a, b). Normal myocardial
wall thickness (arrow) before
coronary ligature (c). After
posterolateral artery ligature,
ischemic area shows a marked
reduction in ventricular thickness
(d).Short axis (e) and long axis (f)
scans showing impaired perfusion
in the apex and in the lateral wall
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Fig. 4 PLLA/GCSF group: planar (a–c), volume rendering (d), end-
diastolic long axis (e), and end-systolic long axis (f) reconstructions
from CT scans. Ischemic area is characterized by a small area of tissue
loss. Patch is radiolucent and is indicated by red arrows. Ventricular
diameter measurements were performed using these sequences (dashed
lines)
Fig. 3 PLLA/CTRL group: long axis (a–e) and short axis (f) planar reconstructions from CT scans. Ischemic area is characterized by a small area of
tissue loss. Patch is radiolucent and is indicated by red arrows
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CTRL group, the polymer appeared poorly cellularized al-
though several inflammatory elements could be detected at
the interface between the polymer and the native tissue.
Differential count of CD68-positive cells in MI/CTRL,
PLLA/CTRL, and PLLA/GCSF showed a statistically signif-
icant higher number of inflammatory cells in the control group
and also in the nonfunctionalized scaffold in respect to the
GCSF-releasing scaffold (Fig. 11). This finding was coupled
with a statitically significant increase in the number of nonin-
flammatory, fibroblast-like vimentin-positive cells in the
GCSF group (Fig. 11). Capillary density measurement
showed a significant increase of neovessels in the PLLA/
GCSF group compared to PLLA/CTRL. Similarly, a
signifcant increase in the number of neovessels could be ob-
served in the PLLA/CTRL group in respect to MI/CTRL
group (Fig. 12). Use of specific markers of angiogenesis
(CD31) allowed to confirm the neoformation of the vascular
structures observed (Fig. 13).
Discussion
The development of functional bioengineered human cardiac
tissue for the treatment of ischemic heart disease is a tremendous
challenge for researchers and physicians. Many scaffold-based
and scaffold-free approaches have been developed over the
years, using natural biological materials such as collagen or fi-
brin, decellularized heart matrix, or synthetic polymers [34–37].
Fig. 5 Exemplificative ECG-gated CT morphovolumetric analysis of a
MI/CTRL subject. Diastolic (a) and systolic (b) acquisition. Definition of
inner and outer margins in long axis (c) and in short axis (d) view,
followed by reconstruction (e). Graphical representation of regional
wall motion with colorimetric scale, where dark areas indicate reduced
kinesis (f)
Table 2 Left ventricle end diastolic volume (LVEDV), left ventricle
end systolic volume (LVESV), ejection fraction (EF), cardiac output
(CO), stroke volume (SV), and left ventricle mass (LVM) measured
with CT scan, 6 weeks post-myocardial infarction
HEALTHY MI/CTRL PLLA/CTRL PLLA/GCSF
EDV (mL) 8 ± 0.3 10 ± 0.6 11 ± 0.5 9 ± 0.3
(P = 0.003) (P = 0.025) (P < 0.001)
ESV (mL) 3 ± 0.2 8 ± 0.3 8 ± 0.4 5 ± 0.5
(P < 0.001) (P < 0.001) (P < 0.001)
EF (%) 63 ± 0.3 33 ± 0.4 35 ± 0.2 43 ± 0.1
(P < 0.001) (P < 0.001) (P < 0.001)
SV (mL) 5 ± 0.6 2 ± 0.2 3 ± 0.3 4 ± 0.4
(P = 0.032) (P < 0.001) (P = 0.007)
CO (L/min) 0.66 ± 0.5 0.25 ± 0.6 0.37 ± 0.8 0.51 ± 0.5
(P = 0.686) (P = 0.546) (P = 0.777)
LVM (g) 9 ± 0.3 5 ± 0.2 6 ± 0.4 7 ± 0.6
(P = 0.001) (P = 0.007) (P = 0.032)
P values refer to the difference with PLLA/GCSF group
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Some approaches rely on thin patches with well-aligned and
electrically coupled cardiomyocytes, while cell-containing scaf-
folds are more easily vascularized by the host’s circulation.
Patches can also be functionalized for the codelivery of peptides
or other molecules promoting cell survival, control of inflamma-
tion, or improving cell function as a therapeutic modality for
patients with ischemic heart disease [35].
The results of this preliminary study showed that (1) a
PLLA-based electrospun scaffold efficiently integrated into a
chronic infarcted myocardium without eliciting a strong in-
flammatory response; (2) functionalization of the biopolymer
with GCSF led to a greater degree of cellular colonization
wi t h i n mic rome t r i c f i b e r s in compa r i son to a
nonfunctionalized scaffold; (3) PLLA/GCSF polymer in-
duced a angiogenetic process with a statistically significant
increase in the number of neovessels in respect to the
nonfunctionalized scaffold; (4) PLLA/GCSF implanted at
the level of the infarcted zone induced a reorganization of
Fig. 6 Heart exposure through
left thoracotomy (a), with vessel
identification after pericardial
suspension (b). Macroscopic
evaluation of the infarcted heart in
MI/CTRL group (c, d).
PLLA/GCSF patch (arrow) is
integrated in myocardial tissue,
visible as a white sheet (e, f)
Fig. 7 Myocardial infarction size among groups after 4 weeks (light
gray) and 6 weeks (dark gray) after induced myocardial infarction.
Myocardial infarction size is expressed as the percentage of the left
ventricular myocardial volume
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the ECM architecture leading to connective tissue deposition
and scar remodeling; and (5) these findings were coupled with
a statistically significant reduction in ESV and EDV, indicat-
ing an inhibitory effect of the scaffold on ventricular dilation,
and an improvement in cardiac performance.
GCSF might play a pivotal role in ischemic cardiac remod-
eling with potential tremendous implication in future clinical
practice. GCSF was found to be associated with antiapoptotic
effect and inhibitory action on ventricle remodeling [8]. These
effects are thought to be dependent on the receptor responsible
for cardiac hypertrophy and via Akt pathway in failing ventri-
cle after MI [38]. Recently, Rosenberg et al. demonstrated that
the interaction between BM-derived stem cells and
cardiomyocytes leads to a modified gene expression and in-
duction of antiapoptotic pathways via a paracrine activation of
Akt signaling [39]. These findings may at least in part explain
the cardioprotective effects of stem cell therapy. Interestingly,
Baldo et al. showed that GCSF reduces infarct size, preserves
cardiac function, and prevents post-ischemic heart failure de-
velopment in rats by an increase in Bcl-2 and Bcl-xL protein
expression, eventually leading to an attenuation of apoptosis
in the damaged tissue [40].
Also, GCSF activates the Wnt and Jak2 signals in cardiac
cells leading to upregulation of connexin 43 (Cx43) protein
Fig. 9 Qualitative assessment of ECMwithMasson’s (upper panels) and
Silver staining (lower panels) of the infarcted area. Denser, thicker, and
scarcely organized collagen bundles are found in the MI/CTRL and
PLLA/CTRL group at the level of the scar, while the PLLA/GCSF was
characterized by a looser reticular organization of the collagen which
appeared interspread among several neovessels
Fig. 8 H/E staining of the infarcted area, with ×10 (upper panel) and ×40 magnification (lower panel). Myocardial tissue showed typical features of
chronic infarction with nuclear picnosis (black arrows) and intercellular patchy calcifications (arrowheads)
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expression and increasing its localization on the plasma mem-
brane [41]. Cx43 is the major constituent of cardiac gap junc-
tion complex and is crucial for the regulation of the electrical
properties of the heart reducing susceptibility to lethal arrhyth-
mia after MI [42, 43]. In an in vivo small animal model of MI,
GCSF treatment was shown to prevent ventricular arrhythmia
associated to MI, reduce the duration of sustained ventricular
tachycardia and improve survival [41]. To this extent, Baldo
et al. have very recently suggested that GCSF might exert a
direct stabilizing electrophysiological effect on infarcted myo-
cardium independently of its genomic effects; in fact, its ad-
ministration before coronary ligature in rats reduces the inci-
dence of ventricular premature beats and ventricular tachycar-
dia also in the following 30 min after MI occurrence [44].
Additionally, GCSF was found to enhance effects on angio-
genesis [45], to induce in macrophages the synthesis of matrix
metalloproteases (MMPs) that normally brings to adverse re-
modeling of ECM [46, 47], and to stimulate differentiation of
muscular precursor cells to myotubes [48]. In light of these
findings, several experimental efforts have been conducted to
understand the molecular mechanism underlying GCSF ef-
fects and to optimize its in vivo and clinical use [49]. To
prevent repeated drug administration and potentially
associated complications, considering the 3.5-h half-life of
GCSF, different solutions have been developed. Local injec-
tion of growth factor encapsulated hydrogels into skeletal
muscle was gradually replaced by innovative metastable com-
posite poly(ethylene glycol)-based hydrogel, obtaining a use-
ful tool for controlled and sustained GCSF delivery and yield-
ing extended mobilization of mononuclear cells and expanded
CD34+ and CD31+ endothelial progenitor cells (EPCs)
in vivo for up to 4 days [50]. However, even if controlled
and sustained, the systemic delivery of cytokines or growth
factors for regenerative purposes has shown inconsistent re-
sults in clinical trials and is also accompanied by numerous
safety concerns and side effects [51].
Clearly, cardiac regeneration requires a complex cascade of
events that cannot underestimate the structural and functional
importance of the cardiac tissutal niche, along with factors and
biological changes occurring in the microenvironment of the
injured myocardium beyond the cellular counterpart. A real
regenerative medicine approach should consider the signifi-
cance of the ECM and the strong biological and physical sig-
nals that it can provide and receive [10]. The connective tissue
atmosphere and the structural microenvironment in which
cells are embedded affect their function and support their
Fig. 10 PLLA/GCSF patch in its site of implantation (grossly marked
with black arrows, because of the partial integration with myocardial
tissue), with evidence of angiogenesis (red arrows) (a H/E staining,
magnification ×10). Phase-contrast image with specific polarized light,
showing the bifrangent polymer (b). Magnifications of a (×40) (c) and b
(×40) (d)
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proliferation and differentiation. The creation of suitable struc-
tures (scaffolds), where the correct biochemical signals guide
the growth of functional neotissue and provide an appropriate
surface for cell attachment, proliferation, differentiation, and
migration, appears crucial in this scenario [5, 52]. Tissue en-
gineering (TE) approaches allowing for manufacturing of
scaffolds tailored to promote and enhance tissue repair and
regeneration are therefore emerging as a valid alternative.
Scaffolds of poly-ethyl-acrylate and the self-assembling pep-
tide gels are known to improve the uniformity and density of
cell colonization in 3D structure [53], and this technology was
previously found to be effective in engineering a functional
heart muscle in vitro [54]. Another useful biofabrication tech-
nique is represented by electrospinning which enables to man-
ufacture fibrillary matrix with ultrastructural properties featur-
ing in micrometric scale and thus closely simulating the native
ECM histoarchitecture [17]. In our group, we focused on the
development of ECM-mimicking scaffolds for cardiac tissue
engineering purposes and a GCSF-functionalized scaffold has
been produced by electrospinning [16].
The biological and mechanical properties of the scaffold
used in this study have been previously described in other
work from our group [16]. To overcome many of the biolog-
ical, economical, logistic, and ethical concerns which are
currently known to hurdle the clinical application of cellular
therapy, we decided to explore a strategy that avoids the use of
cells but mostly relies on the biomimetic design of the scaffold
and its paracrine effect as a Bdrug-eluting device,^ and might
therefore be introduced in clinical practice more rapidly. With
this in mind, and differently from other published approaches
[55, 56] based on the application of tissue-engineered con-
structs in an acute context immediately after the experimental
generation of aMI, we used a chronicized stabilizedMImodel
infarction which reflects the normal conditions routinely en-
countered by surgeons in the clinical scenario. In light of this
translational vocation, the scaffold was not pre-seeded with
stem cells before implantation as was the case for other de-
scribed approaches [55, 56]. Tissutal resident stem cells and
progenitor cells known to inhabit specific niches in the heart
[57, 58], or bone marrow-derived stem cells recruited after a
myocardial injury could therefore colonize an artificial matrix
that, for its internal structure, closely simulates the native
ECM atmosphere and actively emanates biological signals to
support their survival and differentiation. This 3D ECM-like
environment would therefore promote and boost the endoge-
nous reparative process triggered by organ damage.
In our setting, the scaffold, by mimicking the ECM
histoarchitecture, provided at the same time a biological and
mechanical support during the healing process, exerting a
modulatory effect on cell colonization, and guiding and ac-
companying the body regenerative response. Noteworthy, our
findings are consistent with a more controlled and modulated
tissutal reaction in the PLLA/GCSF group, as testified by the
reduced presence of inflammatory cells in this group. The
biological signaling arising from the scaffold could mitigate
the host response reducing the intensity of the inflammatory
phase of the healing process (as confirmed by both radiolog-
ical and histological observations) and orientate cellular reac-
tion toward effective regeneration. The biomimetic principle
inspiring the structure of this scaffold, along with the
functionalization with bioactive molecules, allowed to guide
the reparative processes and modulate the microenvironment
of the damaged tissue favoring the regenerative drive over the
inflammatory reaction.
GCSF-induced angiogenesis is well known in the literature
[59–62], but in this setting, it occurred in the context of the
implanted scaffold. Histological analysis showed a significant
number of neovessels within the scaffold framework. The bio-
polymer provided both stimuli and structural support to an-
giogenesis, guiding this process also from the spatial and to-
pographical point of view. This finding could achieve an im-
portant significancewhen considering the clinical incidence of
situations in which small coronaries caliber or scarcity of col-
lateral flow in myocardial zones involved by ischemic injury
impede to perform coronary artery bypass (CABG) [63]. In
situ-guided angiogenesis through the use of tissue-engineered
drug-releasing scaffolds might be an attractive alternative to
Fig. 11 Count of CD68-positive (a) and vimentin-positive cells (b)
among the three groups
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create a Bneoangiogenetic bypass^ in myocardial regions
which cannot be revascularized, as an adjunct to routinely
used autologous grafts.
In our study, neoangiogenesis was associated to significant
increase in cardiac performance as testified by measurements
of EF, stroke volume, and cardiac output along with the frac-
tion of shortening of the LV. Also, we found a significant
reduction of EDVand ESV, reliably indicating that the benefit
on cardiac performance can be due to a restraint action exerted
by the biopolymer engrafted in the myocardial wall. This
finding might be reliably explained by a phenomenon of com-
pensatory hypertrophy induced by the biomaterial, or, alterna-
tively, by a significant cellular colonization of the patch lead-
ing to production of new extracellular matrix. However, the
reshaping effect induced by the surgical implant of the patch
itself with consequent reduction of LV cavity could invalidate
this hypothesis. Nevertheless, the improvement in LV vol-
umes has been found in the PLLA/GCSF group only, while
both the MI/CTRL and the PLLA/CTRL group showed a
progressive dilation of LV chambers. Therefore, the reshaping
effect observed in PLLA/GCSF group is unlikely to be due to
a Bsuction cup^ effect. Clearly, further investigations are re-
quired to elucidate the mechanisms underlying these findings.
In the PLLA/GCSF group, a dense cellularization with
subsequent organization in a neotissue was observed histolog-
ically, while the PLLA group showed a scarce cellular colo-
nization. This finding is in line with the known chemotactic
effect of GCSF; however, the immunological analysis of the
origin of the cells populating the scaffold can be useful to
explain these histological observations. However, the inflam-
matory reaction was not exuberant indicating a good degree of
biocompatibility of the material within the host tissue.
Fig. 13 Immunohistochemistry for CD31-positive cells, indicating a higher degree of neoangiogenesis in PLLA/GCSF group
Fig. 12 Capillary density measurement (magnification ×40) in MI/
CTRL (a), PLLA/CTRL (b), and PLLA/GCSF (c) groups, with
quantitative evaluation (d). Capillary density measurement showed a
significant increase of neovessels in the PLLA/GCSF group compared
to PLLA/CTRL (p value <0.01). Similarly, in the PLLA/CTRL group
versus MI/CTRL group (p value <0.01)
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Differential cell count for inflammatory and noninflammatory
cells showed a stastistically significant lower number of in-
flammatory element in the GCSF group. In parallel, vimentin-
positive cell number was higher in the functionalized scaffold
group suggesting a shift in the ratio between inflammatory and
fibroblast-like cells. Taken together, these finindings support
the mentioned idea of a more modulated inflammatory re-
sponse accompanied by an active reparative response.
Athough we mainly used vimentin as a fibroblastic marker
to investigate ECM neoformation, Odorfer et al. and parallely
Antonistitis et al. intriguigly used this protein as a marker of
early differentiated cardiomyocites [31, 64]. Despite in need
of confirmatory study, the increased presence of early differ-
entiated cardiomoycites in the PLLA/GCSF scaffold might
open novel fascinating avenues in in situ tissue engineering
and fuel further research on this field.
Along with this finding, the imaging analysis through CT
demonstrated a significant increase in the ventricular mass in
the PLLA/GCSF group. Beside the caveat of the low sample
size and the resolution and technical limits of the imaging
system used, this data might confirm the histological observa-
tion of the constitution of neotissue or might suggest a phe-
nomenon of a compensatory LV hypertrophy induced by the
biopolymer. In the latter hypothesis, we could speculate that
GCSF with its known antiapoptotic effects might have posi-
tively influenced the delicate balance between apoptosis and
hypertrophy known to characterize post-MI ventricular
remodeling.
Our results are similar to the ones by Zhang’s group, who
used a fibrin patch to enhance production and delivery of
cytokines from vascular cells for myocardial repair. In vitro
experiments proved that the functionalized patch reduced
myocyte apoptosis and contractile dysfunction, and that
patch-enhanced cell therapy was associated with a reduced
infarct size and enhanced angiogenesis 4 weeks after MI
[65, 66]. However, these results were obtained using a cell-
based approach in which progenitor cells delivered by a fibrin
patch and liberating a plethora of biochemical signals induced
angiogenesis and improvement in cardiac function. Despite
using different Bmyocardial enhancers,^ those similar results
suggest that many cofactors might ultimately convey into a
unique—unknown—final mechanism of action which trig-
gers tissue repair, and that the use of smart ECM-mimicking
biopolymers delivering the correct sequence of biological sig-
naling might produce similar benefit without the addition of
exogenous cells sources. Future studies are warranted to elu-
cidate this point and provide a comprehensive view of these
phenomena, but there are several studies in support of this
hypothesis reporting approaches based on injectable polymer-
izing hydrogels exhibiting natural cellular adhesion sites and
capable of reproducing the mechanical properties of the
nanofibrous network of the ECM [67]. In in vivo studies, these
injectable polymers were able to increase LV myocardial wall
thickness, limiting the LV remodeling process and preserving
myocardial contractility [68].
Despite preliminary and purely speculative in its nature,
this study is demonstrating the effectiveness of a GCSF-
releasing polymer in a model of chronic myocardial infarction.
Differently from the current paradigm in TE and cardiovascu-
lar regenerative medicine, the described approach does not
imply the use of exogenous stem cells but relies on the opti-
miza t ion o f the b ioma te r i a l des ign and on i t s
biofunctionalization with the aim to create a device able to
simulate the native histoarchitecture of the cardiac ECM and
modulate the microenvironment of the infarcted myocardium
through the release of growth factors. The biomaterial
engrafted in the host tissue would emanate a biological signal
able to stimulate the reparative process and orientate the re-
generative potential and the differentiation of endogenous
stem cell resources resident in the heart or migrated from other
organs.
Almost 10 years ago, the pioneering works of Chachques
and Carpentier on collagen-based sponges for myocardial re-
pair culminated in the Magnum trial which evaluated the ef-
fect of cell-seeded collagen scaffolds on the myocardial scar in
patients undergoing coronary surgery, but this approach still
included the use of autologous mononuclear bone marrow
cells (BMCs) with the economical and logistic issues associ-
ated to cell therapy [69]. However, recent meta-analysis of
randomized clinical trials concluded that intracoronary autol-
ogous BMC treatment, which is more practical and technical
feasible than the patient-specific fabrication of a living myo-
cardial construct, led to an improvement in EF and ameliorat-
ed ventricular remodeling over time after implantation. Those
results are associated with reduced hospital admission for
heart failure, recurrent myocardial infarction, or angina [70,
71]. In front of these evidences and if a Bstem cell-free
approach^ is not successful, a challenging perspective could
be therefore the evaluation of intravascular autologous periph-
eral stem cell administration, used as a Bburst therapy ,^ com-
bined with the local application after myocardial revasculari-
zation of functionalized scaffolds able to provide a sustained
delivery of growth factors and a platform to recruit and locally
capture the stem cells injected. By conveying various effects,
myocardial perfusion could be enhanced by the positive re-
modeling due to the cellular and ECM-surrogate interplay.
Limitations
Among the limitations of this study, authors acknowledge the
lack of a cytofluorimetric and immunophenotypic analysis of
the cells colonizing the scaffolds and in blood stream to dem-
onstrate the chemotactic effect of GCSF. The scarcity of spe-
cific antibody to detect rabbit markers limited this study.
Secondly, a more detailed quantitative and qualitative analysis
of the neomatrix (collagen type I, collagen type III elastin,
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etc.) deposited within the biopolymer to support the findings
on the geometrical remodeling of the LV is lacking. Similarly,
apoptosis and proliferation analysis along with an evaluation
of the presence of neoangiogenetic factors such as VEGF or
bFGF might be useful to address questions on induced LV
hypertrophy. Considering the known effect of GCSF in the
upregulation of Cx43 and prevention of malignant ventricular
arrhythmia, an immunological analysis of the expression of
this marker might be advocated although no arrhythmias were
registered at ECG throughout the study. These parameters are
currently under evaluation in our group.
Another limitation relies in the lack of quantitation of the
potential GCSF release from the patch in to the systemic cir-
culation. In this study, in order to avoid biases related to the
presence of connective tissue in the epicardium, which might
have affected the results and also the diffusion of the mole-
cules, we scarified the infarcted region before implantation to
guarantee a direct contact of the patch with the myocardial
muscle and microvessels. GCSF diffusion was analyzed and
characterized in our previous foundation study. However, the
scarcity of specific antibody to detect rabbit markers
prevented to perform an actual quantitative assay (i.e.,
ELISA) to measure systemic GCSF released by the scaffold.
However, based on our previous analysis in vitro [16], we
might reliably speculate that the actual amount reaching the
circulation is negligible and that the functional activity was
exerted locally.
Finally, despite the sample size has been calculated using
reverse power analysis on the bases of previously published
reports in this field, a larger number of observations might be
required to confirm the findings here described.
Clinical Significance
A GCSF-functionalized PLLA scaffold implanted on an in-
farcted zone induced a neoangiogenetic response and a reor-
ganization of the ECM architecture leading to connective tis-
sue remodeling with a positive impact on ventricle remodeling
and performance. Scaffold was not pre-seeded with stem cells
but was used as a Bsmart^ biomaterial with the rationale to
boost the endogenous reparative response exploiting the bio-
mimetic design of the scaffold and the biological signaling
emanated. Indeed, the biomaterial was able to stimulate and
modulate the physiological process of repair in the absence of
exogenous sources of cells. This might indicate its potential
for a use in the clinical scenario as an Boff-the-shelf^ device,
circumventing the logistical economical and ethical issues re-
lated to stem cell therapy. In light of this translational inspira-
tion, the animal model was selected to simulate as closely as
possible the clinical conditions encountered by surgeons in the
routine practice. Additionally, the finding of local enhance-
ment of angiogenesis in the surrounding area of an infarct
could also achieve an important significance when
considering the incidence of situations in which small coro-
naries caliber or scarcity of collateral flow in ischemic myo-
cardial zones impede to perform CABG. In situ-guided angio-
genesis by tissue-engineered drug-releasing scaffolds might
be an attractive alternative to create a Bneoangiogenetic
bypass^ in myocardial regions which cannot be
revascularized, as an adjunct to routinely used autologous
grafts. This study represents the first pre-clinical experience
proving a role for PLLA/GCSF scaffold in myocardial infarc-
tion and, if confirmed by further investigations, might support
the introduction of such scaffolds into the clinical scenario in
patients undergoing surgical myocardial revascularization.
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